Chemistry:Acridine carboxamide
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H19N3O |
| Molar mass | 293.370 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.[citation needed]
While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]
See also
- Ondansetron, an isomer of Acridine carboxamide
References
- ↑ "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational New Drugs 21 (3): 347–52. August 2003. doi:10.1023/A:1025476813365. PMID 14578683.
- ↑ "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". European Journal of Cancer 38 (1): 70–4. January 2002. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842.
- ↑ "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Annals of Oncology 13 (5): 777–80. May 2002. doi:10.1093/annonc/mdf121. PMID 12075748.
- ↑ "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". European Journal of Cancer 39 (3): 330–4. February 2003. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.
 |  |
